 CAMBRIDGE, Mass., April 28, 2021 GLOBE NEWSWIRE -- Trillium Therapeutics Inc. NASDAQTSX: TRIL, a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today provided a data update, announced Phase 1b2 program priorities across seven hematologic and solid tumor indications, and reported governance changes with its Board of Directors. 